KIMBERLY GAMBINO: Open Payments
NPI 1730343393 · MUNFORDVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$609 in 29 payments from 12 companies in 2025. Trend: 2023 $797 · 2024 $1,010 · 2025 $609
Food & beverage: $609
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $79 |
| Alkermes, Inc. | 4 | $68 |
| Teva Pharmaceuticals USA, Inc. | 2 | $66 |
| Supernus Pharmaceuticals, Inc. | 4 | $64 |
| ABBVIE INC. | 3 | $60 |
| E.R. Squibb & Sons, L.L.C. | 2 | $49 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Lundbeck LLC | 1 | $30 |
| Janssen Pharmaceuticals, Inc | 1 | $23 |
Products named: INGREZZA, TRINTELLIX, AUSTEDO XR, Qelbree, ARISTADA, COBENFY, Auvelity, VRAYLAR.
Industry payments across KY — which companies pay providers there.
